ESMO 2017 Highlights in Gynaecological Cancers: Hight Quality Data From Randomised Trials

Speaker: Mansoor Mirza

Mansoor Mirza comments on some very important results from phase III trials presented this year at the ESMO 2017 Congress. These findings confirm the standard of care for cervical and new or relapsed ovarian cancer.

Mansoor Mirza comments on some very important results from phase III trials presented this year at the ESMO 2017 Congress. These findings confirm the standard of care for cervical and new or relapsed ovarian cancer.

Sudeep Gupta reported on a trial comparing neoadjuvant chemotherapy plus surgery to standard therapy of cisplatin plus radiotherapy in women with stage IB2 to IIB squamous cervical cancer. It shows that chemoradiation remains the state of the art for this group of patients.

Andrew Clamp presents the result of the ICON8 study which doesn’t confirm the results of a previous study conducted in Japanese populations. In the Caucasian European population, the standard of 3-weekly scheduling of carboplatin/paclitaxel should remain the standard of care in patients with epithelial ovarian cancer.

PARP inhibitors have changed the course of disease for ovarian cancer patients. Jonathan Ledermann explains that the maintenance PARP inhibitor rucaparib significantly improved PFS in recurrent ovarian cancer patients responding to platinum-based chemotherapy with higher benefits for BRCA mutated patients (11 months difference in median PFS).

Abstracts

  • 928O_PR - Neoadjuvant chemotherapy followed by surgery (NACT-surgery) versus concurrent cisplatin and radiation therapy (CTRT) in patients with stage IB2 to IIB squamous carcinoma of cervix: A randomized controlled trial (RCT)
  • 929O_PR - ICON8: A GCIG Phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line Epithelial Ovarian/ Fallopian Tube/ Primary Peritoneal Carcinoma (EOC) treatment: Results of Primary Progression- Free Survival (PFS) analysis
  • LBA40_PR - ARIEL3: A Phase 3, Randomised, Double-Blind Study of Rucaparib vs Placebo Following Response to Platinum-Based Chemotherapy for Recurrent Ovarian Carcinoma (OC)
  • 930O - Quality of Life in Patients with Recurrent Ovarian Cancer (OC) Treated with Niraparib: Results from the ENGOT-OV16/NOVA Trial

More resources from ESMO 2017 Congress